https://www.peakprosperity.com/forum-topic/covid-news-you-can-use/ – A good outline by a self described "former lab director of a large medical center in Southern California, board certified in both Anatomic and Clinical Pathology with emphasis in microbiology".
https://www.researchgate.net/publication/7679870_Good_ACE_bad_ACE_do_battle_in_lung_injury_SARS – ACE2 protects against lung injury by SARS, published in Nature.
If ACE2 cannot be upregulated pharmacologically, there are ARB (AT1R) blockers, which seem to mitigate the cascade of pro-inflammatory effects, and therefore, increased incidence of serious complications as a result of increased Angtiotensin II. Remember that COVID-19 seems to use ACE2 as a pathway into host cells, similarly to SARS.
PS: For those who need a refresher of the RAS: https://www.semanticscholar.org/paper/Trilogy-of-ACE2%3A-a-peptidase-in-the-system%2C-a-SARS-Kuba-Imai/c4b3097c2bf40d1c75ca5e8c2b334742cd836545/figure/1
Source: Original link